Bajaj Healthcare Q4 FY26: ₹22.85 Cr loss, PAT -60%

What Bajaj Healthcare reported for Q4 FY26

Bajaj Healthcare reported a standalone net loss of ₹22.85 crore for Q4 FY26, swinging from a net profit of ₹11.17 crore in Q4 FY25. The quarter ended March 31, 2026 was described by management as challenging, with pricing pressure in domestic active pharmaceutical ingredients (APIs) and early effects of geopolitical disruptions in West Asia. Revenue was broadly stable year-on-year, but profitability turned negative on the reported numbers. The company also disclosed that its annual profitability was impacted by one-off items, which shaped the full-year picture more than operating trends alone.

Revenue trend: small decline, but two reported quarterly figures

On revenue from operations, one set of disclosed numbers showed a 0.91% year-on-year decline to ₹153.05 crore in Q4 FY26 from ₹154.47 crore in Q4 FY25. Another report on the same results period stated quarterly revenue declined 7.16% year-on-year to ₹156.01 crore. Both figures point to a quarter where top-line growth was limited despite management citing “high teens volume growth” year-on-year. The difference in reported quarterly revenue figures reflects that multiple summaries of the results were in circulation, but each indicates broadly stable-to-soft revenue for the quarter.

Profitability: loss at PAT and PBT levels

The company posted a pre-tax loss of ₹20.80 crore in Q4 FY26, compared with a profit before tax of ₹11.72 crore in Q4 FY25. At the net level, the swing was sharper, with the reported net loss of ₹22.85 crore against a profit of ₹11.17 crore a year earlier. The disclosures also highlighted “Profit After Tax from continuing operations before exceptional items” registering 19% year-on-year growth, indicating that exceptional or non-operating items played a significant role in the reported loss. Investors tracking the results therefore had to separate underlying operating performance from exceptional impacts.

EBITDA and margin: near-flat EBITDA, slight margin improvement

EBITDA stood at ₹25.33 crore in Q4 FY26, down 1.17% year-on-year. Even with a small decline in EBITDA, the EBITDA margin improved to 16.7% from 16.4% in Q4 FY25. That suggests cost control and mix helped the margin, even as pricing pressure and raw material costs were cited as headwinds. Management pointed to operational discipline and cost management as key factors supporting profitability metrics before exceptional items.

Segment mix: domestic APIs down, formulations up

Segment-wise data showed domestic API revenue declined 2.56% year-on-year to ₹86.85 crore in Q4 FY26. API exports fell 5.42% to ₹38.54 crore during the quarter. In contrast, the formulations business recorded a sharp increase, with revenue rising 27.67% year-on-year to ₹27.67 crore. The quarter therefore showed pressure in both domestic and export APIs, while formulations offered growth and diversification.

Key numbers snapshot (Q4 FY26 vs Q4 FY25)

Management commentary: pricing pressure and West Asia disruption

Managing Director Anil Jain said the quarter faced a “challenging operating environment” driven by continued price erosion in domestic APIs and early impacts of disruptions in West Asia, including elevated raw material prices. He also said revenue remained broadly stable year-on-year despite high-teens volume growth. In the same remarks, the company highlighted that profitability from continuing operations before exceptional items grew 19% year-on-year, framing the quarter’s operating performance as more resilient than the reported PAT suggested. The commentary also emphasised operational discipline and cost management as key levers.

Full-year FY26: revenue up, profit down on exceptional items

For FY26, one report said net profit after tax fell 60.08% year-on-year to ₹15.77 crore, even as annual revenue grew 9.99% to ₹618.17 crore. The profit decline was attributed mainly to a ₹33.25 crore exceptional loss linked to the reversal of technical know-how income, along with ₹5.54 crore of losses from discontinued operations. Separately, audited results data indicated revenue from operations for FY26 rose to ₹611.03 crore from ₹542.60 crore in FY25, while profit before tax declined about 37% to ₹28.92 crore from ₹46.01 crore. The same audited summary also said Total Comprehensive Income fell to ₹16.38 crore from ₹40.87 crore.

FY26 exceptional reversal: what the company linked it to

The reversal of income of about ₹33.24 crore was linked to regional instability in the Middle East, which affected a customer’s ability to meet commitments tied to a technical know-how arrangement. This item was cited as the key driver behind the year-on-year fall in profitability, despite higher revenue. Management also said FY26 revenue grew 12.6% year-on-year, driven by API export growth of 51.6% year-on-year with traction across the EU, UK, LATAM, and other regulated markets, alongside 12.6% growth in the formulations business. It also stated PAT margin from continuing operations before exceptional items rose to 8.8% from 7.9% in FY25.

Market reaction: stock closes lower

Shares of Bajaj Healthcare fell 0.88% to close at ₹336.90 on the BSE following the update. A separate market report headline also noted the stock was down 8% after the results, underlining that price reaction varied across trading sessions and reporting windows. The reported close at ₹336.90 captures the immediate move referenced alongside the quarterly loss headline.

Why the update matters for investors

The quarter’s reported loss, combined with the sharp full-year profit decline, highlights how exceptional items and reversals can dominate headline earnings even when revenue is relatively stable. The segment split shows formulations are becoming a more meaningful contributor, while API pricing remains a risk factor, particularly in the domestic market. Management’s focus on “continuing operations before exceptional items” and comments on cost discipline indicate it wants investors to look beyond the one-offs. The next few quarters will likely be watched for how the API environment, raw material costs, and execution in formulations and CDMO translate into reported earnings without large exceptional adjustments.